AP NEWS
ADVERTISEMENT
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

Lexaria Bioscience: Turning the Tide on Hypertension

April 15, 2021 GMT

New York, NY - ( NewMediaWire ) - April 15, 2021 - PCG Digital -- Hypertension, or high blood pressure, is known as the “silent killer” because it causes more than  7 million deaths  each year-often with  next to no symptoms.  Hypertension puts people at greater risk for heart disease and stroke, the leading causes of death in the United States, according to the Centers for Disease Control. Nearly half of adults in the United States have high blood pressure or are currently taking medication for hypertension-and very few have it under control.

ADVERTISEMENT

Fortunately, there is good news on the horizon, as Lexaria Bioscience (Nasdaq: LEXX) aims to turn the tide on hypertension. 

While the  three leading hypertension  drugs available on the market can save lives, they also cause a lot of unwanted side effects-everything from headaches to nausea to dizziness to fatigue. Despite having already notched more than $100 billion in sales, these medications are problematic for many.



Cannot view this video? Visit:
https://www.youtube.com/watch?v=8m-vPilohPI

DehydraTECH to revolutionize hypertension market 

That’s where DehydraTECH CBD by Lexaria comes in. This revolutionary oral deliverable for hypertension sufferers is set to be a market game-changer with its potential for minimal side effects and maximum effectiveness. 

Using a patented dehydration process that changes how the body senses and absorbs drugs orally, DehydraTECH CBD has been shown to deliver 300% more CBD than generic CBD in less than 30 minutes. It is  in human clinical trials right now  with already promising results.

“Our 2018 human clinical trial showed that DehydraTECH CBD lowers blood pressure by about 5% after just a single 90 milligram dose,” said Lexaria CEO Chris Bunka. “Generic CBD doesn’t do that. Our objective in our new 2021 clinical studies is to evidence a 10% or greater drop in blood pressure to be competitive with industry demands.”

Lexaria believes it can evidence a 10 to 20% reduction in blood pressure in studies during the next six to nine months-the competitive standard for successful hypertension drugs. “In the hypertension industry, drugs that provide a 10 to 20 percent reduction in blood pressure are generally successful,” Bunka adds. “We are confident we can get to that level and expect our studies to provide evidence supporting that this year.” 

ADVERTISEMENT

While the trials are in process, the company continues to examine smart ways to commercialize DehydraTECH CBD as a regulated form of CBD.

Partnering for better health outcomes

To tap into the  almost $30 billion hypertension market, Lexaria will look to partner with Big Pharma in delivering this potentially life-saving treatment. With animal trial results expected in May and human clinical results in September, as well as industry precedents that are already established, the path to commercialization is becoming clear.

Likewise, with existing patents granted in the EU and Australia for the treatment of heart disease using cannabinoids, Lexaria is anticipated to achieve regulatory approvals in multiple geographic markets.

All of this is great news for the many people across the globe who suffer from hypertension and for those seeking a better treatment alternative.

Disclaimer

This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit  www.pcgadvisory.com/disclosures.

Contact:  info@pcgadvisory.com